Molecular biology of the androgen receptor

Tags: androgen receptor, prostate cancer, Cancer Res, AR, androgen receptor gene, J Urol, cancer, gene, Mol Endocrinol, Kemppainen JA, androgen receptors, steroid hormone receptor, gene mutations, the AR, glucocorticoid receptor, American Society of Clinical Oncology, ligand-binding, ligand binding, Prostatic intraepithelial neoplasia, steroid hormone receptors, androgen deprivation therapy, prostate carcinoma, LBD, nuclear receptor, J Biol Chem, ligand binding domain, Mol Cell Endocrinol, gene amplification, Transcriptional regulation, Hum Mol Genet, prostate epithelium, prostatic cancer, estrogen receptor, binding domain, prostatic cancer patient
Content: BIOLOGY OF NEOPLASIA Molecular Biology of the Androgen Receptor
By Edward P. Gelmann
Abstract: Androgen receptor (AR) is a member of the steroid hormone receptor family of molecules. AR primarily is responsible for mediating the physiologic effects of androgens by binding to specific DNA sequences that influence transcription of androgenresponsive genes. The three-dimensional structure of the AR ligand-binding domain has shown it is similar to other steroid hormone receptors and that ligand binding alters the protein conformation to allow binding of coactivator molecules that amplify the hormone signal and mediate transcriptional initiation. However, AR also undergoes intramolecular interactions that regulate its interactions with coactivators and influence its activity. A large number of naturally occurring mutations of the human AR gene have provided important
information about AR molecular structure and intermolecular interactions. AR is also a critical mediator of prostate cancer promotion, conferring growth signals to prostate cancer cells throughout the Natural history of the disease. Late-stage prostate cancer, unresponsive to hormonal deprivation, sustains AR signaling through a diverse array of molecular strategies. Variations in the AR gene may also confer genetic predisposition to prostate cancer development and severity. Further understanding of AR action and new strategies to interfere with AR signaling hold promise for improving prostate cancer therapy. J Clin Oncol 20:3001-3015. © 2002 by American Society of Clinical Oncology.
O NE ONLY HAS TO compare even very young children to imagine that the effects of the androgen receptor (AR) have broad developmental and psychologic effects even at the earliest stages of life. Moreover, AR has important effects throughout life, ranging from the obvious effects on pubertal development to the physiologic dysregulation that contributes to male pattern baldness, to the genesis of prostatic hyperplasia, and later in life to prostate cancer. The diverse effects of AR are mediated by complex cell type-specific signaling pathways. During the past several years, there have been a number of new insights into the mechanism of AR action in normal cells. Detailed molecular genetic analyses elucidating the functional domains of the AR molecule and the deciphering of the three-dimensional crystal structure of the ligand-binding domain (LBD) have both markedly expanded our understanding of AR molecular physiology. Moreover, research into the molecular pathology of prostate cancer has shown that the AR gene is a target for mutation or amplification in prostate cancer cells and therefore plays a critical role in the pathogenesis and tumor progression of this very common cancer. This review will attempt to place these new findings into context, provide an overview of our current understanding of AR structure, and describe current understanding of its role in prostate cancer. Other reviews on AR, its coactivators, physiology, endocrinology, and its role in prostate cancer should also be consulted.1-10 The AR gene is located on the X chromosome and therefore is single-copy in males, which allows for the phenotypic manifestation of mutations without the influence of a wild-type codominant allele. Medical geneticists have
cataloged more spontaneous mutations of human AR than of any other gene in part because AR is not essential to the formation of a viable human organism. Descriptions of the structure-function relationships of these mutations have shed important light on functional domains of the AR molecule. Complete loss of AR function in genetic (XY) males results in the complete androgen insensitivity syndrome manifest as phenotypic, though sterile, females who, significantly, are accepting of their sex identity.11 This suggests that AR is a critical developmental trigger not only for male morphologic development but also for configuration of the male CNS. Missense mutations that attenuate AR activity are responsible for partial androgen insensitivity syndrome. For a comprehensive review of the developmental impact of AR and of the androgen insensitivity syndromes, the reader is referred to the article by Quigley et al.7 From the Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, 3800 Reservoir Rd NW, Washington, DC. Submitted October 3, 2001; accepted April 5, 2002. Supported by grant nos. CA87855 and CA96854 from the National Institutes of Health, Bethesda, MD. Address reprint requests to Edward P. Gelmann, MD, Department of Oncology, Lombardi Cancer Center, Georgetown University School of Medicine, 3800 Reservoir Rd NW, Washington, DC 20007-2197; email: [email protected] © 2002 by American Society of Clinical Oncology. 0732-183X/02/2013-3001/$20.00
Journal of Clinical Oncology, Vol 20, No 13 (July 1), 2002: pp 3001-3015 DOI: 10.1200/JCO.2002.10.018
Fig 1. Genomic organization of the AR gene is shown. The genome spans more than 80 kb that includes the exonic organization shown in the second panel. Location of three codon repeat regions in the first exon that codes for the N-terminal domain is shown in the third panel. The diagram of the protein structure demonstrates how the exon organization translates into discrete functional regions of the receptor. Adapted from Quigley et al.7
AR GENE CHROMOSOMAL LOCATION AND GENE STRUCTURE The AR gene is located on chromosome Xq11-12.12,13 The gene is oriented with the 5' end toward the centromere and spans ~ 90 kb of DNA containing eight exons that code for a ~ 2,757-base pair open reading frame within a 10.6-kb mRNA14-17 (Fig 1). AR is a member of the steroid hormone receptor family of genes. Like the other members of this family of transcription factors, the exons of the AR gene code for functionally distinct regions of the protein similar to the modular structure of other steroid hormone receptor genes. The AR genomic organization is conserved throughout mammalian evolution from rodents to man. Indeed, the location of AR on the X chromosome is preserved in other animals, such as marsupials and monotremes, and may reflect a developmentally significant association of AR with other syntenic genes.18 The first exon codes for the Nterminal domain (NTD) that is the transcriptional regulatory region of the protein. Exons 2 and 3 code for the central DNA-binding domain (DBD). Exons 4 to 8 code for the C-terminal LBD.
CAG REPEATS The first exon contains several regions of repetitive DNA sequences. Most noteworthy of these is a CAG triplet repeat that begins at codon 58 and extends for an average of 21 2 repeats.19 There is some degree of evolutionary conservation of CAG repeats. Rats and mice have short stretches of CAG repeats that correspond to the CAG repeat region in the human AR that codes for a polyglutamine stretch beginning at amino acid 57. Rat and mouse AR have longer polyglutamine stretches that begin at amino acid 175 in both rodent proteins. Since these polyglutamine stretches are found at different locations from human AR, they may have different functional significance. The CAG repeat region is present in primate AR genes, and its length decreases with evolutionary distance from humans, which suggests that the CAG repeat region may have developmental or behavioral implications for the most advanced species.20 Like other genes with CAG triplet repeats, the length of this region is highly polymorphic because of slippage of DNA polymerase on the multiple CAG nucleotides in the DNA template resulting in variability in the final number of CAG repeats
MOLECULAR BIOLOGY OF THE ANDROGEN RECEPTOR copied during DNA Replication. The range of CAG repeat length is 14 to 35 repeats in a group of males and may vary somewhat with ethnicity and race.21,22 The CAG triplet codes for the amino acid glutamine (Q). The length of the CAG repeat unit can affect AR activity and influences prostate cancer risk (see below). The presence of a CAG triplet repeat places the AR in the category of genes for which excessive extension of the CAG repeat can result in an inherited neuromuscular degenerative disease. Kennedy's disease or spinal and bulbar muscular atrophy is caused by extension of the AR CAG repeat length to 40 to 62 repeats.19 Individuals with Kennedy's disease develop progressive neurologic impairment caused by degeneration of spinal motor neurons and muscle wasting in the fourth through sixth decades of life. The neurologic manifestations of Kennedy's disease are due to the fact that proteins containing excessively long polyglutamine stretches induce neuronal cell apoptosis, an important pathogenic mechanism in some neurodegenerative diseases.23-26 Further confirmation for the pathogenesis of Kennedy's disease comes from the appearance of neurodegenerative disease in mice expressing an AR transgene with expanded CAG repeat.27 Interestingly, Kennedy's disease is also accompanied by androgen insensitivity caused by attenuated activity of the AR with a long poly-Q region in the NTD.19 AR TRANSCRIPTION Transcription of the AR gene is cell-type specific and also age-specific in some tissues. Moreover, AR mRNA levels are regulated by androgen and by other steroid hormones. The promoter region of the AR gene lacks typical TATA and CAAT sequences in the region immediately 5' to the start of the mRNA. As is not uncommon with TATA-less genes, the 5' untranslated region of the gene contains GC-rich sequences that bind the transcription factor SP1.17,28 The AR gene is transcribed from at least two separate promoter start sites whose activities vary depending on cell type.29 Studies of the rat AR gene promoter have identified binding sites for a wide range of transcriptional activators.28 Consistent with its widespread effects, AR is expressed in cells of a wide range of tissues far beyond primary and secondary sexual organs. In fact, except for the spleen, it is difficult to find a tissue that does not express some amount of AR (reviewed in7,10). Not only is there tissue-specific control of AR transcription but also agedependent variations that have been observed in rat liver that is mediated by transcription factor binding to specific target sequences in the promoter.30,31 The rat AR promoter also contains palindromic DNA binding sites recognized by the AR, the glucocorticoid
3003 receptor, and the progesterone receptor.28,32 AR action is regulated to some degree by negative feedback to transcription of the AR gene itself. Castration results in increased AR mRNA that is reversed by administration of androgen.33,34 Rat AR expression is downregulated by androgen and by the gonadotropin follicle-stimulating hormone, which may act by inducing cyclic AMP for which the AR promoter contains a response element.35-38 EVOLUTIONARY CONSERVATION OF AR Conservation of segments of the AR gene throughout evolution implicates these regions as being critical for the activity of the molecule. The DBD is most highly conserved from Xenopus to human, and the LBD is also highly conserved. Other regions of the gene that retain a striking concentration of sequence conservation include much of the hinge region and the LBD.39 Consistent with the biologic requirement that the AR molecule bind its cognate ligand, 12 of the 43 conserved codons of the LBD map to the coding region for the ligandbinding pocket. A large number of LBD sites that are targets for mutation resulting in androgen insensitivity syndrome are conserved from frog to man. In addition, the hinge region, particularly its N-terminal domain, is also highly conserved from frog to rodent.39 The NTD, encoded by the first exon, displays virtually no conservation from frog to rodent to man upstream from codon 539 in the human sequence. However, sequence comparison of NTDs from primates reveals that codons 1 to 53 and 360 to 429 generate conserved protein segments across a broad evolutionary spectrum.40 These regions are important for dimerization of human AR and their genetic conservation reflects functional similarity for all primate AR molecules. AR PROTEIN STRUCTURE AND ACTIVITY LBD During the last 2 years, the three-dimensional structure of the AR LBD has been determined.41,42 The AR LBD structure has now been added to the catalog of steroid hormone receptor family members whose LBDs have been analyzed crystallographically. Among these are estrogen receptors alpha and beta,43-45 progesterone receptor, Vitamin D Receptor, retinoic acid receptors RXR and RAR-alpha, thyroid hormone receptors, and peroxisome proliferatoractivating receptors.46 Despite substantial differences in the primary amino acid sequence between the AR LBD and other steroid hormone receptors, in some cases as low as 20% similarity, the three-dimensional structures of the LBDs of these molecules are quite similar. The LBDs of these receptors fold into 12 helices that form a ligandbinding pocket (Fig 2A). When an agonist is bound, for
EDWARD P. GELMANN example, to the estrogen receptor, helix 12 folds over the pocket to enclose the ligand. When an antagonist is unbound, helix 12 is positioned away from the pocket in a way that interferes with the binding of coactivators to a groove in the hormone-binding domain formed after ligand binding.43 In AR, ligand binding that induces folding of helix 12 to overlie the pocket discloses a groove that binds a region of the NTD. Coactivator molecules can also bind to this groove, but the predominant site for coactivator binding to AR is in the NTD.47,48 AR ligand resides in a pocket and primarily contacts Q711, M745, and R752 at the A ring of the steroid backbone and L704 and N705 at the C ring. Thus helices 4, 5, and 10 are the primary AR contact regions for ligand binding (Fig 2B). Whereas estrogen receptor and thyroid hormone receptor LBDs form dimers in crystal structure, the crystal structure of the ligand-bound AR LBD is monomeric.41,42 Since there is evidence to suggest that ligand-bound, full-length AR dimerizes in vivo, it is likely that the N-terminal region of AR is important for protein dimerization (see below). Another difference between AR and other steroid hormones receptors is that no identifiable helix 2 can be found in the AR LBD. DBD The DBD includes 70 amino acids that are encoded by exons 2 and 3 and is the region best conserved among the steroid hormone receptors. The DBD amino acid sequence of human AR is 100% identical to rat AR. Among other human steroid hormone receptors, the AR DBD is 79% identical to progesterone receptor, 76% identical to glucocorticoid receptor, and 56% identical to estrogen receptor-alpha. The DNA-binding region includes eight cysteine residues that form two coordination complexes, each composed of four cysteines and a Zn2 ion. These two zinc fingers form the structure that binds to the major groove of DNA49 (Fig 3). Assuming that AR DNA binding behaves identically to glucocorticoid receptor, K580 and R585 in the first zinc finger bind, respectively, to the second and fifth nucleotide pairs in the first androgen-response element (ARE) repeat GGTACA.50-54
Fig 2. Three-dimensional structure of the AR LBD. (A) A ribbon diagram of the AR LBD is shown with the ligand in the binding pocket. The 12 helices are numbered as are the N and C termini of the LBD, Note that the ligand-binding pocket is formed by helices 3, 5, and 10. (Reprinted and modified from Sack et al42 by permission from the publisher.) (B) Detailed view of the AR ligand-binding pocket. Note that T877, the site of the LNCaP and many prostate cancer mutations, makes direct contact with the ligand. Alternation of 877 or other amino acids shown result in conformational changes in the binding pocket that broaden the scope of molecules that can be accommodated. (Revised by Stanley R. Krystek, Bristol-Myers Squibb,
from a figure in Sack et al.42 Printed with permission of the publisher.) (C) Three-dimensional structure of the AR LBD with pathogenic mutations. The colored spheres indicated the location of mutations that affect the LBD in prostate cancer and androgen insufficiency syndromes. Mutations observed in prostate cancer are represented in red; those observed for CAIS are shown in yellow, and those observed for PAIS/MAIS are in cyan. Mutation of one residue (M749) is implicated in both prostate cancer and CAIS and is represented in orange. (Figure and part of the legend reprinted by permission from Matias et al.41)
Fig 3. Amino acid sequence of the AR DBD showing the formation of two zinc fingers that are each configured due to binding of four cysteine residues to a zinc ion. Three residues in boxes, G, S, and V, are highly conserved among steroid hormone receptors such as progesterone and glucocorticoid receptor and are the sites of contact with the ARE. The nuclear localization signal sequence (NL in circle) is C-terminal to the DBD. (Adapted from Hiipakka and Liao189 and printed by permission of the publisher.) The second zinc finger stabilizes the binding complex by hydrophobic interactions with the first finger and contributes to specificity of receptor DNA binding.55 The second finger also is necessary for receptor dimerization that occurs during DNA binding.51,56 The ARE in DNA is composed of two palindromic hexanucleotide half sites separated by a three-nucleotide spacer.53 There is substantial variation between the AREs seen in different promoter regions. However, single nucleotide differences in AREs affect the affinity of different receptors for DNA and can influence the relative effects of different steroid hormone receptors on specific promoter regions.57 In addition, the presence of multiple AREs in a promoter region causes tandem promoter binding and enhancement of AR specificity and action.58-60 In fact, individual AREs in general have low activity in in vitro assays of transcription. Androgen-induced transcriptional activity that mimics transcriptional activation seen in cells requires the presence of a number of AREs arranged in the correct spatial orientation.61-63 Therefore, specificity for hormone action must be dictated to some extent by other regions of the receptor and interaction with other cis-acting elements that participate in transcriptional initiation.64,65 Moreover, there are two classes of ARE that cooperate to enhance AR binding to DNA and may be critical for determining specificity of hormonal responsiveness of a promoter. AR will bind to guanine residues indicated by underlined letters in the sequence RGAACA-NGN-TGTNCT. AR will also bind to a second class of ARE, RGGACA-NNA-AGCCAA,
that mediates cooperation between adjacent bound receptors and enhances the specificity of androgen responsiveness.66 NTD The NTD is the primary effector region of AR and is largely responsible for transactivation. Deletion of the LBD from the AR results in a residual N-terminal fragment with constitutive activity nearly equal to the transcriptional activity of the ligand-bound, full-length protein. This differs from other steroid hormone receptors whose activity is attenuated by deletion of the C-terminal LBD and suggests that the primary site for interaction of AR with coactivator molecules that amplify the transcriptional signal and mediate AR action is via the NTD. The NTD is the region of AR with the least evolutionary conservation. There is only 20% amino acid identity between human and rat NTD. Therefore, it is not surprising that this region has some functional characteristics that are unique compared with other members of the steroid hormone receptor family. The first 140 amino acids are not essential for transcriptional activity. Their deletion results in a receptor with nearly wild-type levels of activity. However, deletion of regions further downstream, between amino acids 210 and 337, markedly reduce receptor activity.67 In studies of intramolecular AR interactions, it was shown that amino acids 142 to 337 were not required for receptor dimerization. However, deletions of 14 to 150 reduced and of 339 to 499 eliminated regions that mediate interaction with the LBD.68-70 Further discussion of the NTD follows in the next section. MOLECULAR MECHANISMS OF AR ACTION Before ligand binding, many steroid hormone receptors reside in the cytoplasm, where they are sequestered by binding to chaperone molecules such as heat shock proteins. The entry of ligands into the Cell Results in receptor binding causing a conformational change that releases heat shock proteins and allows the steroid hormone receptor to be translocated to the nucleus.71-76 Although studies with AR in some experimental systems suggest that before ligand binding the receptor is cytoplasmic, it is possible that endogenous AR may in fact reside largely in the nucleus (E. Wilson, Personal communication, September 2001). Subcellular localization of AR may also be cell-type specific.77,78 Nuclear targeting of AR is influenced by the hinge region, where a deletion markedly reduces ligand-induced nuclear translocation but does not totally block signaling.67,79 AR also contains two basic nuclear targeting regions similar to nucleoplasmin, a histone-binding protein.77 Regulation of steroid hormone receptor action occurs, in part, by posttranslational modification, such as phosphorylation.80 Phosphorylation of steroid hormone receptors oc-
3006 curs under different conditions and for apparently different reasons depending on the receptor. For example, phosphorylation of progesterone receptor is both hormone-dependent and important for transcriptional activation.81,82 On the other hand, there are multiple phosphorylation sites on glucocorticoid receptor, none of which seem to be necessary for receptor activity. AR is phosphorylated on at least three sites, S81, S94, and S650. The first two were not important for AR activity in some experimental systems, but their physiologic role has not been determined. AR is phosphorylated at a number of sites in response to agonist binding that result in nuclear localization, but usually not in response to antagonists.83-85 Recently, it was shown that S81 phosphorylation is regulated in response to steroid hormones and S650 in response to forskolin and phorbol ester, which implies a regulatory role for S650 phosphorylation in signal transduction mediated by cyclic AMP and protein kinase C (D.G. Gioeli and M.J. Weber, personal communication, September 2001). In contrast to the other phosphorylation sites, the S650 site in the hinge region is required for full AR transcriptional activity.86 Serine 308 has also been shown to be a target for phosphorylation, although its physiologic role is unknown.87 Even in the cytoplasm, before nuclear translocation, ligand-bound steroid hormone receptors have biologic effects. Both AR and estrogen receptor can bind to homologous or heterologous ligands in the cytoplasm and exert inhibitory effects on cell death processes.88 However, these effects are of relatively low magnitude compared with the profound effects on cell growth, survival, and differentiation that occur when ligand-bound steroid hormone receptors enter the nucleus.89 Ligand-bound steroid hormone receptors bind to specific DNA sequences and initiate the formation of a protein complex at the promoter region of hormone-responsive genes that initiates transcription.90 Whereas several steroid hormone receptors have been observed to form homodimers in solution and in crystal structure,91 AR has not been observed to form a homodimer in vitro in the absence of a DNA-binding sequence.42,92 The binding of steroid hormone receptors to DNA is the first step in the assembly of a protein complex on the DNA that amplifies the signal initiated by steroid hormone receptor binding. Steroid hormone receptor action is mediated by a family of coactivator proteins that amplify the signal, mediate CREB-binding protein recruitment to the receptor complex, and initiate RNA polymerase activity.93 Steroid hormone receptor action is attenuated by the binding of corepressor molecules that inhibit transcriptional initiation.94 The binding of corepressor molecules is favored when antihormones occupy the ligand-binding pocket.95,96 AR triggers assembly of activated transcriptional complexes
EDWARD P. GELMANN at an ARE in response to dihydrotestosterone binding, but complexes with the corepressor NCOR when bound to antiandrogens like bicalutamide. The proximity of enhancer elements in the DNA sequence can form additional transcription complexes that align with the primary promoter complex and amplify the formation of a transcriptional complex.97 The binding of p160 coactivators to steroid hormone receptors occurs at a specific groove that is created by the apposition of helices 3, 4, 5, and 12 that is formed after ligand binding.43,98-101 This groove is revealed when helix 12 is positioned over the ligand-binding pocket occupied by a receptor agonist. Helix 12 is displaced from a ligandbinding pocket that contains a receptor antagonist such that helix 12 interferes with coactivator binding. For this reason helices 3, 4, 5, and 12 are the sites of activating factor (AF)-2 activity that was discovered by mutational analysis to be important for p160 coactivator binding.43 Coactivator molecules contain a consensus peptide of the motif LXXLL (L is leucine and X is any amino acid) in a region called the NR box, which binds to the groove in steroid hormone receptors.93,102 Many of these proteins belong to the steroid receptor coactivator family and bind to the AF-2 region in the C terminus of ligand-bound receptors such as the estrogen receptor. Other proteins, such as CREB-binding protein, complex with AR near the DBD to participate in a multiprotein transcriptional complex.90,94,103 Hormone-dependent binding of p160 coactivators through the LXXLL motifs results in the activation of histone acetyltransferase activity, which plays a role in chromatin remodeling to allow for active transcription of DNA.104,105 Whereas estrogen and thyroid hormone receptors, for example, interact with coactivators via contact points in the LBD, AR interaction with coactivators occurs primarily via regions of the NTD.106 Moreover, coactivators interact with the AR NTD via a glutamine-rich region rather than via the LXXLL NR box motif that mediates interaction with estrogen receptor.47 Although coactivator LXXLL motifs may interact with the AR LBD, the AR AF-2 domain seems to be the preferred C-terminal site for interaction with the AR NTD. Interaction between the NTD and LBD of the ligand-bound receptor is essential for AR activity.68-70,107-110 Helix 12 of ligand-bound AR is stabilized by interaction with either of two regions in the AR NTD.106 This interaction facilitates binding of p160 coactivators to AR in a manner that is independent of the LXXLL NR boxes. Moreover, the interaction of N-terminal and AF-2 domains stabilizes receptor-ligand interactions and is required for ligand-dependent activation of the receptor. In fact, two pentapeptide regions of the AR N terminus, 23FQNLF27 (FXXLF) and 433WHTLF437 (WXXLF), mediate binding of
MOLECULAR BIOLOGY OF THE ANDROGEN RECEPTOR the N terminus to the C-terminal region of AR. 23FQNLF27 interacts with the AF-2 groove formed by helices 3, 4, 5, and 12 and competes favorably with LXXLL-containing coactivator proteins for ligand-dependent binding to the LBD.111 The interaction of ligand-bound AR with coactivators is still not wholly understood, since some coactivators interfere with N/C interactions and others enhance those same interactions.108 The pentapeptide 433WHTLF437 also binds to the C-terminal region but at a site outside the AF-2 groove. It may be that this interaction follows ligand binding and is facilitated by interaction between 23FQNLF27 and AF-2 so as to strengthen interactions between AR NTD and LBD.112 In fact, coactivators may be favored for AR binding because of FXXLF pentapeptides that compete favorably with the AR NTD for AF-2.113 The importance of both NTD and LBD for AR activity is underscored by spontaneous mutations in these regions that cause either complete or partial androgen insensitivity. The importance of NTD-LBD interactions are underscored by the fact that complete androgen insensitivity syndrome can be caused by missense mutations in helix 12 and in other regions of the LBD that interact with the NTD.7 Even though the mechanism of interaction between AR and coactivators may differ from that of other steroid hormone receptors, coactivators are still essential for AR action in vivo. This is underscored by the observation that androgen insensitivity syndrome occurred in an individual with a mutation in a coactivator gene and a normal AR gene.114 AR AND PROSTATE CANCER RISK The prostate gland depends on androgens for its development and maintenance of its integrity. Congenital AR dysfunction or deficiency of 5-alpha-reductase in genetic males causes minimal or absent development of the prostate gland.115 In animals, as well, androgens are critical for the integrity of the prostate gland. Within a week of castration, a rat prostate will undergo involution that results from epithelial cell apoptosis.116 Androgens are also a physiologic prostate cancer promoter. Studies of eunuchoid individuals have suggested that prostates remain small and hypertrophy or prostate cancer does not develop.117 Moreover, animal models of prostate carcinogenesis require the presence of functioning testes or exogenous androgens to support the development of prostatic cancer.118,119 Transgenic mice engineered for elevated AR expression in the prostate have high turnover of prostatic epithelial cells and develop prostatic intraepithelial neoplasia later in life.120 Although it is clear that androgens are essential for the development of prostate cancer, it has been difficult to correlate relative levels of serum androgens with prostate cancer risk. Racial differences in circulating androgen levels
3007 have been proposed to account, in part, for differences in prostate cancer incidence and severity. However, the association between prostate cancer incidence and serum androgen levels is controversial and has not been demonstrated conclusively.121-126 This may be due to the fact that the activity of the ligand receptor may vary and may play an equally important role in prostate cancer promotion. Genetic variations in the AR that affect its activity have been shown to affect prostate cancer risk. Since excessive NTD CAG repeat length was associated with hypogonadism in Kennedy's disease, it was suspected that this common polymorphic region could influence AR activity.127 In fact, CAG repeat length is inversely related to AR activity in the right cellular milieu.128 The dependence of these findings on cell type may be due to the effect that the NTD poly-Q region has on interactions with p160 or other coactivator molecules.129 Different studies have shown that shorter CAG repeat length in the AR NTD is associated with the occurrence of more aggressive prostate cancer,130 earlier age of onset,131,132 and likelihood of recurrence.133 Even in low-risk Asian populations that are favored by higher median CAG repeat length, shorter CAG repeat length influences prostate cancer risk.134 One smaller study in a European population failed to support the association between CAG repeat length and prostate cancer risk,135 and CAG repeat length does not seem to play a role in the inheritance of risk we attribute to familial prostate cancer.136 Other alterations of the AR gene, particularly in the 5' untranslated region, have been associated with prostate cancer risk via a still unknown mechanism.137 In contrast to the large number of missense AR mutations that have been found in association with androgen insensitivity syndromes, there do not seem to be many AR mutations that predispose to prostate cancer. One example of an inherited AR mutation that confers prostate cancer risk was found in a Finnish kindred. A missense mutation R726L was initially found in a prostate cancer specimen138 and then shown to be present in the germline of 0.33% of the Finnish population and 1.91% of Finnish prostate cancer patients (odds ratio, 5.8; P .006).139 This rare mutation probably originated from a single Finnish founder and recently has not been found in the American population.140 ALTERATIONS OF THE AR GENE IN PROSTATE CANCER Like the epithelium from which they arise, prostate cancer cells retain responsiveness to and dependence on androgens. It has been know for more than half a century that prostate cancer in most cases retains androgen responsiveness and will undergo regression in response to androgen deprivation.141,142 Over 80% of men with disseminated
3008 prostate cancer will show some clinical response to androgen ablation. However, there is no way to predict which patients will not respond or how long the responding patients will benefit from androgen control of their prostate cancer. Although the median duration of response to hormonal ablation is less than 3 years, response durations range from a few months to many years. Androgen responsiveness in prostate cancer does not correlate with either the presence or the levels of androgen receptor in cancer tissues.143-148 Furthermore, AR expression persists after the patient no longer enjoys clinical remission induced by androgen deprivation. In general, the AR gene is normal and expressed in primary prostate cancer. However, after hormone deprivation therapy, a number of AR gene alterations have been found. These alterations lead to increased sensitivity of the receptor to low levels of circulating androgens and also to the receptor's ability to recognize a broadened spectrum of ligands as potent agonists of AR action. All these findings underscore the general notion that the AR signaling pathway is usually maintained in advanced prostate cancer that progresses after first-line androgen ablative therapy. The use of androgen blockade in the treatment of prostate cancer has expanded in the last 10 years. Because of heightened prostate cancer awareness and intensified screening, more men have been diagnosed with the disease.149 Androgen deprivation therapy had previously been reserved for patients with metastatic prostate cancer but now is in prolonged use for patients with locally advanced disease as an adjunct to irradiation150 and also may be applied earlier to patients with minimal metastatic disease.151 As a result, more patients are subjected to the selective pressures leading to the appearance of AR gene amplification and mutations. Prostate cancer cells respond to hormone deprivation therapy by amplifying AR gene copy number in approximately 25% to 30% of patients who experience disease recurrence. No AR gene amplification was found in pretreatment tissue specimens from the patients in whom AR gene amplification developed.152-154 The presence of AR gene amplification may reflect an adaptation of the cancer cells to castrate levels of circulating androgens. This is consistent with the finding that patients with AR gene amplification at the time of recurrence on hormone ablation have a higher likelihood of responding to second-line hormonal therapy than those without amplification.155-157 Interestingly, amplification of the AR gene is also an adaptive response to high-dose antiandrogen monotherapy, reflecting the importance of increased AR signaling for prostate cancer cells.158 Although there was a suggestion that AR gene amplification was associated with higher levels of circulating prostate-
EDWARD P. GELMANN specific antigen,155 more quantitative analysis of tumor mRNA failed to confirm this association.159 Hormonal deprivation also seems to lead to the selection of mutations in the AR gene that alter its response to antiandrogens and broaden the spectrum of ligand agonists. The first suggestion that prostate cancer cells could have altered AR came with the observation that the hormoneresponsive LNCaP cell line recognized the antiandrogens cyproterone acetate and hydroxyflutamide, the active metabolite of flutamide, as agonists.160 This phenomenon was explained by the demonstration that LNCaP cell AR contained a T877A mutation that was responsible for the altered pharmacologic activity of the antiandrogens.161-163 It should be remembered that LNCaP cells were derived from a patient who had been treated with diethylstilbestrol but for whom antiandrogens were not available.164 Three-dimensional crystallographic analysis has since shown that replacement of the threonine side chain with an alanine alters the size of the steroid-hormone binding pocket to accommodate ligands that the wild-type receptor cannot.42 In particular, the pocket in the variant receptor can accommodate larger residues at position 17 of the D ring in the steroid backbone. The function of most AR mutants identified in prostate cancer has not yet been determined. Recently, a yeast-based assay was developed and tested on 44 AR gene mutations found in prostate cancer. The assay depended on AR activity in yeast and therefore was limited by the complement of coactivators and other molecules available to mediate AR action in yeast. However, this assay demonstrated that there was a wind range of functional ramifications of AR mutations in prostate cancer that ranged from loss to gain of function.165 A number of investigators have detected AR mutations in prostate cancer tissue.166-174 These mutations are very rare AR mutations in patients with primary prostate cancer and are found with higher frequency in patients with advanced disease, which suggests that mutations in AR occur before hormonal ablative therapy and play a role in prostate tumor progression.166 Detection of AR mutations depends somewhat on the sensitivity of the experimental approach. Molecular analysis of prostate cancer tissues faces hurdles because of the heterogeneous nature of the tissue samples and of the tumor itself.175,176 Microdissection of tumor tissue to enrich for cancer cell DNA has yielded a higher fraction of samples with detectable AR mutations.166 Analysis of primary prostate tissues with epitope-specific AR antibodies and careful microdissection disclosed up to 44% AR mutations in prostate cancer samples.177 The latter study analyzed primary prostate cancer resected before the widespread use of prostate-specific antigen testing, which sug-
Fig 4. Three-dimensional structure of the AR LBD demonstrating the location of mutations common to prostate cancer (A and B) and CAIS (C and D). The ribbon diagrams in B and D are oriented with 90 clockwise rotation from the diagrams in Figure 2. (A) Peptide map of AR LBD showing regions with high frequency of AR gene mutations in prostate cancer. Approximately 79% of AR gene LBD mutations in prostate cancer occur in the three colored regions bound by codons 670 to 678 (red), 701 to 730 (yellow), and 874 to 910 (purple). Two mutations have been found in the hinge (H) region (arrow). (B) Three-dimensional ribbon diagram of the AR LBD bound to testosterone (green) showing alpha helix and beta sheet structures. The ligand is in the ligand-binding pocket, and the LXXLL peptide of the p160 coactivator GRIP1 (yellow/red hatched) is docked in the hydrophobic coactivator-binding cleft formed by helices 3, 4, and 12. Amino acid residues in which missense mutations have been identified in prostate cancer are indicated. The color scheme for regions where mutations are localized is the same as in panel A. (C) Peptide map of AR LBD showing regions with high frequency of AR gene mutations in CAIS. Approximately 79% of AR gene LBD mutations in prostate cancer occur in the three colored regions bound by amino acids 688 to 710 (red), 749 to 780 (yellow), and 831 to 866 (purple). (D) Three-dimensional ribbon diagram as in panel B. Amino acid residues in which missense mutations have been identified in CAIS are located in the colored regions corresponding to the map in panel C. Note that the prostate cancer mutations affect only one side of the ligand-binding pocket. The other regions where prostate cancer mutations cluster affect coactivator or corepressor binding. On the other hand, clusters of mutations in CAIS affect regions that make direct contact with ligand or abolish binding to p160 coactivator proteins. (Figure provided by Wayne Tilley. Figure and parts of the legend are reprinted from Buchanan et al2 by permission of the publisher.)
gests that small foci with AR mutations may arise at the later stages of local tumor progression. The selective pressure of antiandrogen therapy results in yet a higher frequency of detectable AR mutations in tissues from men who have progressive disease after receiving antiandrogens, predominantly flutamide.178 Mutant receptors have also been found in prostate cancer cell lines and in nude mouse xenografts, further supporting the notion that AR modified to enhance signaling provide a growth advantage for prostate cancer cells.179,180 The precise incidence rate of AR mutations in prostate cancer is less important than the implications the mutations have for treatment strategy. Selection for AR mutations is probably an important oncogenic step in the development of a subset of prostate cancers. It is apparent that some primary prostate cancers do harbor AR muta-
tions. These mutations arose in the absence of treatment selection and were undoubtedly important for the growth of the primary tumor. AR mutations in prostate cancer cluster in three regions of the molecule.2 In the LBD, mutations cluster in the loop between helices 3 and 4 that is common to many steroid hormone receptors.181 Mutations in the LBD affect the ligand-binding pocket and liberalize the spectrum of AR agonists to a wider range of steroid hormones and pharmaceutical antiandrogens.161,174,180 AR mutations that affect the ligand-binding pocket do not, except for a single site, overlap at all with binding pocket mutations that cause androgen insensitivity.41 Since AR mutations in prostate cancer are selected to enhance AR activity and androgen insensitivity mutations decrease activity, this mutual exclusion is not surprising (Fig 2C).
A second cluster is located in the region 874 to 910 that flanks AF-2, the region that affects binding of p160 coactivator molecules and the AR NTD.182 AR activity is affected in prostate cancer, as well, by alterations in AR coactivators. Hormone-resistant prostate cancer cells often display AR overexpression and overexpression of coactivator molecules important for AR signaling.183 Mutations are also found in the hinge region that borders the DBD and the LBD.41,184 The hinge region seems to be targeted because it affects AR interactions with corepressors and thereby diminishes the efficacy of antiandrogens and may explain the sensitization of AR to ligand interactions in late-stage prostate cancer.184 Just as steroid hormone receptors initiate transcriptional signals that have to be amplified by coactivators, the signals can be silenced by corepressors.94 The hinge region of AR between the DBD and LBD is frequently affected by mutations in prostate cancer. The region 668QPIF671 lies between the hinge and the LBD and forms a hydrophobic cleft that potentially mediates interactions with other proteins, perhaps corepressors. This region is mutated both in prostate cancer and in the transgenic murine prostate cancer TRAMP mouse that develops prostate cancer promoted by organ-specific expression of the simian virus 40 T antigen.2,184,185 Moreover, deletion of the hinge region amino acids 628 to 646 results in significant activation of the AR and marked enhancement of LXXLL-dependent ligand-dependent coactivation.186 Interestingly, this region is essentially never affected by mutations associated with androgen insensitivity. This is consistent with the notion that it is primarily a site for corepressor binding and therefore an important target for mutations in prostate cancer (Fig 4). Alternatively, the hinge region may also modulate NTD binding to LBD via the FXXLF motif in the NTD. NTD binding to the LBD can interfere with p160 coactivator binding to the AF-2 groove of the LBD and in this way may modulate the activity of the AR signaling complex.112 All reported AR mutations found in prostate cancer are cataloged in the Androgen Receptor Gene Mutations Data
Base of the Lady Davis Institute for medical research. The URL for the Androgen Receptor Gene Mutations Database World Wide Web server is CONSIDERATIONS FOR THE FUTURE The last several years have seen a substantial expansion in our understanding of how the AR works and how it differs from other members of the steroid hormone receptor family. It is hoped that these differences will be exploitable in the design of new agents to modulate AR action to achieve clinically important results. We have learned from studying AR mutations from androgen insensitivity syndromes as well as those that occur in prostate cancer. These findings have been complemented with results from a number of laboratories that have characterized in detail the functional interactions of the AR molecule. From these studies, there are four possible targets for pharmacologic intervention: AR binding to ligand, N- and C-terminal interactions, coactivators interaction, and corepressor interactions. As the relationships between each of these interactions and the physiologic manifestations of androgen action are elucidated, the targets for intervention will be clarified and our aim at hitting them will improve. Manipulation of androgen action is used for prostate cancer,187 benign prostatic hyperplasia,188 hypogonadism, anemia,189 control of criminal behavior,190 and treatment of male pattern baldness.191 Continued expansion of our understanding of AR action will contribute to more effective therapies with fewer side effects in all these areas and perhaps more. ACKNOWLEDGMENT John Sack, Stanley Krystek, and Wayne Tilley generously provided figures. Wayne Tilley and Mary Ellen Taplin provided valuable discussions about AR mutations. Tapio Visakorpi and Wayne Tilley read the manuscript and graciously provided criticism. Elizabeth Wilson was also kind enough to review the manuscript and provided data before publication.
1. Roy AK, Lavrovsky Y, Song CS, et al: Regulation of androgen action. Vitam Horm 55:309-352, 1999 2. Buchanan G, Greenberg NM, Scher HI, et al: Collocation of androgen receptor gene mutations in prostate cancer. Clin Cancer Res 7:1273-1281, 2001 3. Janne OA, Moilanen AM, Poukka H, et al: Androgen-receptorinteracting nuclear proteins. Biochem Soc Trans 28:401-405, 2000 4. Taplin ME, Ho SM: Clinical review 134: The endocrinology of prostate cancer. J Clin Endocrinol Metab 86:3467-3477, 2001
5. Bentel JM, Tilley WD: Androgen receptors in prostate cancer. J Endocrinol 151:1-11, 1996 6. Gelmann EP: Androgen receptor mutations in prostate cancer. Cancer Treat Res 87:285-302, 1996 7. Quigley CA, De Bellis A, Marschke KB, et al: Androgen receptor defects: Historical, clinical, and molecular perspectives. Endocr Rev 16:271-321, 1995 8. Chang C, Saltzman A, Yeh S, et al: Androgen receptor: An overview. Crit Rev Eukaryot Gene Expr 5:97-125, 1995
MOLECULAR BIOLOGY OF THE ANDROGEN RECEPTOR 9. Zhou ZX, Wong CI, Sar M, et al: The androgen receptor: An overview. Recent Prog Horm Res 49:249-274, 1994 10. Lindzey J, Kumar MV, Grossman M, et al: Molecular mechanisms of androgen action. Vitam Horm 49:383-432, 1994 11. Wisniewski AB, Migeon CJ, Meyer-Bahlburg HF, et al: Complete androgen insensitivity syndrome: Long-term medical, surgical, and psychosexual outcome. J Clin Endocrinol Metab 85:2664-2669, 2000 12. Lubahn DB, Joseph DR, Sullivan PM, et al: Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240:327-330, 1988 13. Brown CJ, Goss SJ, Lubahn DB, et al: Androgen receptor locus on the human X chromosome: Regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet 44:264-269, 1989 14. Lubahn DB, Brown TR, Simental JA, et al: Sequence of the intron/exon junctions of the coding region of the human androgen receptor gene and identification of a point mutation in a family with complete androgen insensitivity. Proc Natl Acad Sci U S A 86:95349538, 1989 15. Kuiper GG, Faber PW, van Rooij HC, et al: Structural organization of the human androgen receptor gene. J Mol Endocrinol 2:R1-R4, 1989 16. Faber PW, van Rooij HC, Schipper HJ, et al: Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter: The role of Sp1. J Biol Chem 268:9296-9301, 1993 17. Tilley WD, Marcelli M, Wilson JD, et al: Characterization and expression of a cDNA encoding the human androgen receptor. Proc Natl Acad Sci U S A 86:327-331, 1989 18. Spencer JA, Watson JM, Lubahn DB, et al: The androgen receptor gene is located on a highly conserved region of the X chromosomes of marsupial and monotreme as well as eutherian mammals. J Hered 82:134-139, 1991 19. La Spada AR, Wilson EM, Lubahn DB, et al: Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77-79, 1991 20. Choong CS, Kemppainen JA, Wilson EM: Evolution of the primate androgen receptor: A structural basis for disease. J Mol Evol 47:334-342, 1998 21. Macke JP, Hu N, Hu S, et al: Sequence variation in the androgen receptor gene is not a common determinant of male sexual orientation. Am J Hum Genet 53:844-852, 1993 22. Sartor O, Zheng Q, Eastham JA: Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology 53:378-380, 1999 23. Rubin LL, Gatchalian CL, Rimon G, et al: The molecular mechanisms of neuronal apoptosis. Curr Opin Neurobiol 4:696-702, 1994 24. de Cristofaro T, Affaitati A, Feliciello A, et al: Polyglutaminemediated aggregation and cell death. Biochem Biophys Res Commun 272:816-821, 2000 25. Kobayashi Y, Kume A, Li M, et al: Chaperones Hsp70 and Hsp40 suppress aggregate formation and apoptosis in cultured neuronal cells expressing truncated androgen receptor protein with expanded polyglutamine tract. J Biol Chem 275:8772-8778, 2000 26. Kouroku Y, Fujita E, Urase K, et al: Caspases that are activated during generation of nuclear polyglutamine aggregates are necessary for DNA fragmentation but not sufficient for cell death. J Neurosci Res 62:547-556, 2000
3011 27. Abel A, Walcott J, Woods J, et al: Expression of expanded repeat androgen receptor produces neurologic disease in transgenic mice. Hum Mol Genet 10:107-116, 2001 28. Song CS, Her S, Slomczynska M, et al: A distal activation domain is critical in the regulation of the rat androgen receptor gene promoter. Biochem J 294:779-784, 1993 (pt 3) 29. Grossmann ME, Lindzey J, Blok L, et al: The mouse androgen receptor gene contains a second functional promoter which is regulated by dihydrotestosterone. Biochemistry 33:14594-14600, 1994 30. Supakar PC, Song CS, Jung MH, et al: A novel regulatory element associated with age-dependent expression of the rat androgen receptor gene. J Biol Chem 268:26400-26408, 1993 31. Song CS, Rao TR, Demyan WF, et al: Androgen receptor messenger ribonucleic acid (mRNA) in the rat liver: Changes in mRNA levels during maturation, aging, and calorie restriction. Endocrinology 128:349-356, 1991 32. Baarends WM, Themmen AP, Blok LJ, et al: The rat androgen receptor gene promoter. Mol Cell Endocrinol 74:75-84, 1990 33. Tan JA, Joseph DR, Quarmby VE, et al: The rat androgen receptor: Primary structure, autoregulation of its messenger ribonucleic acid, and immunocytochemical localization of the receptor protein. Mol Endocrinol 2:1276-1285, 1988 34. Quarmby VE, Yarbrough WG, Lubahn DB, et al: Autologous down-regulation of androgen receptor messenger ribonucleic acid. Mol. Endocrinol 4:22-28, 1990 35. Blok LJ, Hoogerbrugge JW, Themmen AP, et al: Transient down-regulation of androgen receptor messenger ribonucleic acid (mRNA) expression in Sertoli cells by follicle-stimulating hormone is followed by up-regulation of androgen receptor mRNA and protein. Endocrinology 131:1343-1349, 1992 36. Blok LJ, Themmen AP, Peters AH, et al: Transcriptional regulation of androgen receptor gene expression in Sertoli cells and other cell types. Mol Cell Endocrinol 88:153-164, 1992 37. Lindzey J, Grossmann M, Kumar MV, et al: Regulation of the 5'-flanking region of the mouse androgen receptor gene by cAMP and androgen. Mol Endocrinol 7:1530-1540, 1993 38. Mizokami A, Yeh SY, Chang C: Identification of 3',5'-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Mol Endocrinol 8:77-88, 1994 39. Thornton JW, Kelley DB: Evolution of the androgen receptor: Structure-function implications. Bioessays 20:860-869, 1998 40. Choong CS, Kemppainen JA, Wilson EM: Evolution of the primate androgen receptor: A structural basis for disease. J Mol Evol 47:334-342, 1998 41. Matias PM, Donner P, Coelho R, et al: Structural evidence for ligand specificity in the binding domain of the human androgen receptor: Implications for pathogenic gene mutations. J Biol Chem 275:26164-26171, 2000 42. Sack JS, Kish KF, Wang C, et al: Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proc Natl Acad Sci U S A 98:4904-4909, 2001 43. Shiau AK, Barstad D, Loria PM, et al: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95:927-937, 1998 44. Brzozowski AM, Pike AC, Dauter Z, et al: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753758, 1997
3012 45. Tanenbaum DM, Wang Y, Williams SP, et al: Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci U S A 95:5998-6003, 1998 46. Nolte RT, Wisely GB, Westin S, et al: Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395:137-143, 1998 47. Bevan CL, Hoare S, Claessens F, et al: The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 19:8383-8392, 1999 48. Alen P, Claessens F, Verhoeven G, et al: The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol 19:6085-6097, 1999 49. Hard T, Kellenbach E, Boelens R, et al: Solution structure of the glucocorticoid receptor DNA-binding domain. Science 249:157-160, 1990 50. Gewirth DT, Sigler PB: The basis for half-site specificity explored through a non-cognate steroid receptor-DNA complex. Nat Struct Biol 2:386-394, 1995 51. Luisi BF, Xu WX, Otwinowski Z, et al: Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 352:497-505, 1991 52. Schwabe JW, Neuhaus D, Rhodes D: Solution structure of the DNA-binding domain of the oestrogen receptor. Nature 348:458-461, 1990 53. Schwabe JW, Chapman L, Finch JT, et al: The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements. Cell 75:567578, 1993 54. Rastinejad F, Perlmann T, Evans RM, et al: Structural determinants of nuclear receptor assembly on DNA direct repeats. Nature 375:203-211, 1995 55. Schoenmakers E, Alen P, Verrijdt G, et al: Differential DNA binding by the androgen and glucocorticoid receptors involves the second Zn-finger and a C-terminal extension of the DNA-binding domains. Biochem J 341:515-521, 1999 (pt 3) 56. Dahlman-Wright K, Wright A, Gustafsson JA, et al: Interaction of the glucocorticoid receptor DNA-binding domain with DNA as a dimer is mediated by a short segment of five amino acids. J Biol Chem 266:3107-3112, 1991 57. Nelson CC, Hendy SC, Shukin RJ, et al: Determinants of DNA sequence specificity of the androgen, progesterone, and glucocorticoid receptors: Evidence for differential steroid receptor response elements. Mol Endocrinol 13:2090-2107, 1999 58. Grad JM, Dai JL, Wu S, et al: Multiple androgen response elements and a Myc consensus site in the androgen receptor (AR) coding region are involved in androgen-mediated up-regulation of AR messenger RNA. Mol Endocrinol 13:1896-1911, 1999 59. Rennie PS, Bruchovsky N, Leco KJ, et al: Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene. Mol. Endocrinol 7:23-36, 1993 60. Adler AJ, Danielsen M, Robins DM: Androgen-specific gene activation via a consensus glucocorticoid response element is determined by interaction with nonreceptor factors. Proc Natl Acad Sci U S A 89:11660-11663, 1992 61. Kasper S, Rennie PS, Bruchovsky N, et al: Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J Biol Chem 269:31763-31769, 1994 62. Adler AJ, Scheller A, Robins DM: The stringency and magnitude of androgen-specific gene activation are combinatorial functions of receptor and nonreceptor binding site sequences. Mol Cell Biol 13:6326-6335, 1993
EDWARD P. GELMANN 63. Huang W, Shostak Y, Tarr P, et al: Cooperative assembly of androgen receptor into a nucleoprotein complex that regulates the prostate-specific antigen enhancer. J Biol Chem 274:25756-25768, 1999 64. La Baer J, Yamamoto KR: Analysis of the DNA-binding affinity, sequence specificity and context dependence of the glucocorticoid receptor zinc finger region. J Mol Biol 239:664-688, 1994 65. Dahlman-Wright K, Wright AP, Gustafsson JA: Determinants of high-affinity DNA binding by the glucocorticoid receptor: Evaluation of receptor domains outside the DNA-binding domain. Biochemistry 31:9040-9044, 1992 66. Reid KJ, Hendy SC, Saito JL, et al: Two classes of androgen receptor elements mediate cooperativity through allosteric interactions. J Biol Chem 276:2943-2952, 2001 67. Simental JA, Sar M, Lane MV, et al: Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 266:510-518, 1991 68. Langley E, Kemppainen JA, Wilson EM: Intermolecular NH2-/ carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem 273:92-101, 1998 69. Langley E, Zhou ZX, Wilson EM: Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 270:29983-29990, 1995 70. Doesburg P, Kuil CW, Berrevoets CA, et al: Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36: 1052-1064, 1997 71. Ing NH, Beekman JM, Tsai SY, et al: Members of the steroid hormone receptor superfamily interact with TFIIB (S300-II). J Biol Chem 267:17617-17623, 1992 72. Baniahmad A, Ha I, Reinberg D, et al: Interaction of human thyroid hormone receptor beta with transcription factor TFIIB may mediate target gene derepression and activation by thyroid hormone. Proc Natl Acad Sci U S A 90:8832-8836, 1993 73. Brou C, Chaudhary S, Davidson I, et al: Distinct TFIID complexes mediate the effect of different transcriptional activators. EMBO J 12:489-499, 1993 74. Brou C, Wu J, Ali S, et al: Different TBP-associated factors are required for mediating the stimulation of transcription in vitro by the acidic transactivator GAL-VP16 and the two nonacidic activation functions of the estrogen receptor. Nucleic Acids Res 21:5-12, 1993 75. McEwan IJ, Gustafsson J: Interaction of the human androgen receptor transactivation function with the general transcription factor TFIIF. Proc Natl Acad Sci U S A 94:8485-8490, 1997 76. Schulman IG, Chakravarti D, Juguilon H, et al: Interactions between the retinoid X receptor and a conserved region of the TATA-binding protein mediate hormone-dependent transactivation. Proc Natl Acad Sci U S A 92:8288-8292, 1995 77. Jenster G, Trapman J, Brinkmann AO: Nuclear import of the human androgen receptor. Biochem J 293:761-768, 1993 (pt 3) 78. Gerdes MJ, Dang TD, Larsen M, et al: Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells. Endocrinology 139:3569-3577, 1998 79. Zhou ZX, Sar M, Simental JA, et al: A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor: Requirement for the DNA-binding domain and modulation by NH2terminal and carboxyl-terminal sequences. J Biol Chem 269:1311513123, 1994
MOLECULAR BIOLOGY OF THE ANDROGEN RECEPTOR 80. Moudgil VK: Phosphorylation of steroid hormone receptors. Biochim Biophys Acta 1055:243-258, 1990 81. Denner LA, Weigel NL, Maxwell BL, et al: Regulation of progesterone receptor-mediated transcription by phosphorylation. Science 250:1740-1743, 1990 82. Denner LA, Schrader WT, O'Malley BW, et al: Hormonal regulation and identification of chicken progesterone receptor phosphorylation sites. J Biol Chem 265:16548-16555, 1990 83. Goueli SA, Holtzman JL, Ahmed K: Phosphorylation of the androgen receptor by a nuclear cAMP-independent protein kinase. Biochem Biophys Res Commun 123:778-784, 1984 84. Kuiper GG, Brinkmann AO: Phosphotryptic peptide analysis of the human androgen receptor: Detection of a hormone-induced phosphopeptide. Biochemistry 34:1851-1857, 1995 85. Brinkmann AO, Blok LJ, de Ruiter PE, et al: Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 69:307-313, 1999 86. Zhou ZX, Kemppainen JA, Wilson EM: Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol Endocrinol 9:605-615, 1995 87. Zhu Z, Becklin RR, Desiderio DM, et al: Identification of a novel phosphorylation site in human androgen receptor by mass spectrometry. Biochem Biophys Res Commun 284:836-844, 2001 88. Kousteni S, Bellido T, Plotkin LI, et al: Nongenotropic, sexnonspecific signaling through the estrogen or androgen receptors: Dissociation from transcriptional activity. Cell 104:719-730, 2001 89. Kimura K, Markowski M, Bowen C, et al: Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res 61:5611-5618, 2001 90. Mangelsdorf DJ, Thummel C, Beato M, et al: The nuclear receptor superfamily: The second decade. Cell 83:835-839, 1995 91. Kumar V, Chambon P: The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55:145-156, 1988 92. Wong CI, Zhou ZX, Sar M, et al: Steroid requirement for androgen receptor dimerization and DNA binding: Modulation by intramolecular interactions between the NH2-terminal and steroidbinding domains. J Biol Chem 268:19004-19012, 1993 93. Glass CK, Rose DW, Rosenfeld MG: Nuclear receptor coactivators. Curr Opin Cell Biol 9:222-232, 1997 94. Horwitz KB, Jackson TA, Bain DL, et al: Nuclear receptor coactivators and corepressors. Mol Endocrinol 10:1167-1177, 1996 95. Zhang X, Jeyakumar M, Petukhov S, et al: A nuclear receptor corepressor modulates transcriptional activity of antagonist-occupied steroid hormone receptor. Mol Endocrinol 12:513-524, 1998 96. Smith CL, Nawaz Z, O'Malley BW: Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 11:657-666, 1997 97. Shang Y, Myers M, Brown M: Formation of the androgen receptor transcription complex. Mol Cell 9:601-610, 2002 98. Darimont BD, Wagner RL, Apriletti JW, et al: Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev 12:3343-3356, 1998 99. Nolte RT, Wisely GB, Westin S, et al Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395:137-143, 1998 100. Westin S, Kurokawa R, Nolte RT, et al: Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature 395:199-202, 1998
3013 101. McInerney EM, Rose DW, Flynn SE, et al: Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes Dev 12:3357-3368, 1998 102. Voegel JJ, Heine MJ, Zechel C, et al: TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J 15:3667-3675, 1996 103. Aarnisalo P, Palvimo JJ, Janne OA: CREB-binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci U S A 95:2122-2127, 1998 104. Bjorklund S, Almouzni G, Davidson I, et al: Global transcription regulators of eukaryotes. Cell 96:759-767, 1999 105. Freedman LP: Increasing the complexity of coactivation in nuclear receptor signaling. Cell 97:5-8, 1999 106. He B, Kemppainen JA, Voegel JJ, et al: Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 274:37219-37225, 1999 107. Berrevoets CA, Doesburg P, Steketee K, et al: Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol Endocrinol 12:1172-1183, 1998 108. Ikonen T, Palvimo JJ, Janne OA: Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem 272:29821-29828, 1997 109. Zhou ZX, Lane MV, Kemppainen JA, et al: Specificity of ligand-dependent androgen receptor stabilization: Receptor domain interactions influence ligand dissociation and receptor stability. Mol Endocrinol 9:208-218, 1995 110. Scheller A, Hughes E, Golden KL, et al: Multiple receptor domains interact to permit, or restrict, androgen-specific gene activation. J Biol Chem 273:24216-24222, 1998 111. He B, Kemppainen JA, Wilson EM: FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275:22986-22994, 2000 112. He B, Bowen NT, Minges JT, et al: Androgen-induced NH2and COOH-terminal interaction inhibits p160 coactivator recruitment by activation function 2. J Biol Chem 276:42293-42301, 2001 113. He B, Minges JT, Lee LW, et al: The FXXLF motif mediates androgen receptor-specific interactions with coregulators. J Biol Chem 277:10226-10235, 2002 114. Adachi M, Takayanagi R, Tomura A, et al: Androgen-insensitivity syndrome as a possible coactivator disease. N Engl J Med 343:856-862, 2000 115. Griffin J: Androgen resistance: The clinical and molecular spectrum. N Engl J Med 326:611-618, 1992 116. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostrate after castration. Endocrinology 122:552-562, 1988 117. Wu CP, Gu FL: The prostate in eunuchs. Prog Clin Biol Res 370:249-255, 1991 118. Pollard M, Luckert PH, Sporn MB: Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res 51:3610-3611, 1991 119. Pollard M, Luckert PH: The inhibitory effect of 4-hydroxyphenyl retinamide (4-HPR) on metastasis of prostate adenocarcinomaIII cells in Lobund-Wistar rats. Cancer Lett 59:159-163, 1991
3014 120. Stanbrough M, Leav I, Kwan PW, et al: Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci U S A 98:10823-10828, 2001 121. Ghanadian R, Puah CM, O'Donoghue EPN: Serum testosterone and dihydrotestosterone in carcinoma of the prostate. Br J Cancer 39:696-699, 1979 122. Ahluwalia B, Jackson MA, Jones GW, et al: Blood hormone profiles in prostate cancer patients in high risk and low risk populations. Cancer 48:2267-2273, 1981 123. Drafta D, Proca E, Zamfir V, et al: Plasma steroids in benign prostatic hypertrophy and carcinoma of the prostate. J Steroid Biochem 17:689-693, 1982 124. Zumoff B, Levin J, Strain GW, et al: Abnormal levels of plasma hormones in men with prostate cancer: Evidence toward a "twodisease" theory. Prostate 3:579-588, 1985 125. Osegbe DN, Ogunlewe JO: Androgen concentration in blacks with benign and malignant prostatic disease. J Urol 140:160-164, 1988 126. Nomura A, Heilbrun LK, Stemmermann GN, et al: Prediagnostic serum hormones and the risk of prostate cancer. Cancer Res 48:3515-3517, 1988 127. Sobue G, Doyu M, Morishima T, et al: Aberrant androgen action and increased size of tandem CAG repeat in androgen receptor gene in X-linked recessive bulbospinal neuronopathy. J Neurol Sci 121:167-171, 1994 128. Beilin J, Ball EM, Favaloro JM, et al: Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: Specificity in prostate and non-prostate cell lines. J Mol Endocrinol 25:8596, 2000 129. Irvine RA, Ma H, Yu MC, et al: Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum Mol Genet 9:267-274, 2000 130. Giovannucci E, Stampfer MJ, Krithivas K, et al: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci U S A 94:3320-3323, 1997 131. Hardy DO, Scher HI, Bogenreider T, et al: Androgen receptor CAG repeat lengths in prostate cancer: Correlation with age of onset. J Clin Endocrinol Metab 81:4400-4405, 1996 132. Bratt O, Borg A, Kristoffersson U, et al: CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br J Cancer 81:672-676, 1999 133. Nam RK, Elhaji Y, Krahn MD, et al: Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression. J Urol 164:567-572, 2000 134. Hsing AW, Gao YT, Wu G, et al: Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population-based case-control study in China. Cancer Res 60:51115116, 2000 135. Correa-Cerro L, Wohr G, Haussler J, et al: (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur J Hum Genet 7:357-362, 1999 136. Lange EM, Chen H, Brierley K, et al: The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer. Cancer Epidemiol Biomarkers Prev 9:439-442, 2000 137. Crocitto LE, Henderson BE, Coetzee GA: Identification of two germline point mutations in the 5'UTR of the androgen receptor gene in men with prostate cancer. J Urol 158:1599-1601, 1997
EDWARD P. GELMANN 138. Elo JP, Kvist L, Leinonen K, et al: Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol. J Clin Endocrinol Metab 80:3494-3500, 1995 139. Mononen N, Syrjakoski K, Matikainen M, et al: Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene. Cancer Res 60:6479-6481, 2000 140. Gruber SB, Chen H, Tomsho LP, et al: The Finnish R726L audrogen receptor mutation is uncommon in prostate cancer families in the United States. Am J Hum Genet 69:247, 2001 (suppl 4, abstr) 141. Huggins C, Stevens RE, Hodges CL: Studies on prostatic cancer: II. The effect of castration on clinical patients with carcinoma of the prostate. Arch Surg 43:209, 1941 142. Huggins C, Hodges CV: Studies on prostatic cancer: Effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941 143. Sadi MV, Walsh PC, Barrack ER: Immunohistochemical study of androgen receptors in metastatic prostate cancer: Comparison of receptor content and response to hormonal therapy. Cancer 67:30573064, 1991 144. Trachtenberg J, Walsh PC: Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 127:466-471, 1982 145. Gonor SE, Lakey WH, McBlain WA: Relationship between concentrations of extractable and matrix-bound nuclear androgen receptor and clinical response to endocrine therapy for prostatic adenocarcinoma. J Urol 131:1196-1201, 1984 146. Benson RC Jr, Gorman PA, O'Brien PC, et al: Relationship between androgen receptor binding activity in human prostate cancer and clinical response to endocrine therapy. Cancer 59:1599-1606, 1987 147. Rennie PS, Bruchovsky N, Goldenberg SL: Relationship of androgen receptors to the growth and regression of the prostate. Am J Clin Oncol 11:513-517, 1988 (suppl 2) 148. Castellanos JM, Galan A, Calvo MA, et al: Predicting response of prostatic carcinoma to endocrine therapy. Lancet 1:448, 1982 (letter) 149. Hankey BF, Feuer EJ, Clegg LX, et al: Cancer surveillance series: Interpreting trends in prostate cancer--Part I. Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst 91:1017-1024, 1999 150. Bolla M, Gonzalez D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997 151. Messing EM, Manola J, Sarosdy M, et al: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341:1781-1788, 1999 152. Visakorpi T, Hyytinen E, Koivisto P, et al: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 9:401-406, 1995 153. Koivisto P, Visakorpi T, Kallioniemi OP: Androgen receptor gene amplification: A novel molecular mechanism for endocrine therapy resistance in human prostate cancer. Scand J Clin Lab Invest Suppl 226:57-63, 1996 154. Miyoshi Y, Uemura H, Fujinami K, et al: Fluorescence IN SITU HYBRIDIZATION evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients. Prostate 43:225-232, 2000
MOLECULAR BIOLOGY OF THE ANDROGEN RECEPTOR 155. Koivisto PA, Helin HJ: Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma. J Pathol 189:219-223, 1999 156. Koivisto P, Kononen J, Palmberg C, et al: Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57:314-319, 1997 157. Palmberg C, Koivisto P, Kakkola L, et al: Androgen receptor gene amplification at primary progression predicts response to combined androgen blockade as second line therapy for advanced prostate cancer. J Urol 164:1992-1995, 2000 158. Palmberg C, Koivisto P, Hyytinen E, et al: Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. Eur Urol 31:216-219, 1997 159. Linja MJ, Savinainen KJ, Saramaki OR, et al: Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61:3550-3555, 2001 160. Wilding G, Chen M, Gelmann EP: Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. The Prostate 14:103-115, 1989 161. Veldscholte J, Voorhorst-Ogink MM, Bolt-de Vries J, et al: Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: High affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta 1052:187-194, 1990 162. Veldscholte J, Ris-Stalpers C, Kuiper GGJ, et al: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 173:534-540, 1990 163. Veldscholte J, Berrevoets CA, Ris-Stalpers C, et al: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 41:665-669, 1992 164. Horoszewicz JS, Leong SS, Chu TM, et al: The LNCaP line: A new model for studies on human prostatic carcinoma. Prog Clin Biol Res 37:115-132, 1980 165. Shi XB, Ma AH, Xia L, et al: Functional analysis of 44 mutant androgen receptors from human prostate cancer. Cancer Res 62:14961502, 2002 166. Marcelli M, Ittmann M, Mariani S, et al: Androgen receptor mutations in prostate cancer. Cancer Res 60:944-949, 2000 167. Barrack ER: Androgen receptor mutations in prostate cancer. Mt Sinai J Med 63:403-412, 1996 168. Culig Z, Hobisch A, Hittmair A, et al: Androgen receptor gene mutations in prostate cancer: Implications for disease progression and therapy. Drugs Aging 10:50-58, 1997 169. Wang C, Uchida T: Androgen receptor gene mutations in prostate cancer [in Japanese]. Nippon Hinyokika Gakkai Zasshi 88: 550-556, 1997 170. Suzuki H, Sato N, Watabe Y, et al: Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem Mol Biol 46:759-765, 1993 171. Newmark JR, Hardy DO, Tonb DC, et al: Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci U S A 89:6319-6323, 1992 172. Wallen MJ, Linja M, Kaartinen K, et al: Androgen receptor gene mutations in hormone-refractory prostate cancer. J Pathol 189: 559-563, 1999
3015 173. Castagnaro M, Yandell DW, Dockhorn-Dworniczak B, et al: Androgen receptor gene mutations and p53 gene analysis in advanced prostate cancer [in German]. Verh Dtsch Ges Pathol 77:119-123, 1993 174. Taplin ME, Bubley GJ, Shuster TD, et al: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398, 1995 175. Macintosh C, Stower M, Reid N, et al: Precise microdissection of human prostate cancer reveals genotypic heterogeneity. Cancer Res 58:23-28, 1998 176. Gelmann EP: Androgen receptor mutations in prostate cancer. Cancer Treat Res 87:285-302, 1996 177. Tilley WD, Buchanan G, Hickey TE, et al: Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res 2:277-285, 1996 178. Taplin ME, Bubley GJ, Ko YJ, et al: Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res 59:2511-2515, 1999 179. Zhao XY, Boyle B, Krishnan AV, et al: Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol 162:2192-2199, 1999 180. Tan J, Sharief Y, Hamil KG, et al: Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11:450-459, 1997 181. Wurtz JM, Bourguet W, Renaud JP, et al: A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 3:87-94, 1996 182. Gregory CW, Johnson RT Jr, Mohler JL, et al: Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61:2892-2898, 2001 183. Gregory CW, He B, Johnson RT, et al: A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61:4315-4319, 2001 184. Buchanan G, Yang M, Harris JM, et al: Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol Endocrinol 15:46-56, 2001 185. Greenberg NM, DeMayo F, Finegold MJ, et al: Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 92:3439-3443, 1995 186. Wang Q, Lu J, Yong EL: Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. J Biol Chem 276:7493-7499, 2001 187. Crawford ED, Nabors W: Hormone therapy of advanced prostate cancer: Where we stand today. Oncology 5:21-28, 1991 188. Gormley GJ, Stoner E, Bruskewitz RC, et al: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327:1185-1191, 1992 189. Teruel JL, Marcen R, Navarro-Antolin J, et al: Androgen versus erythropoietin for the treatment of anemia in hemodialyzed patients: A prospective study. J Am Soc Nephrol 7:140-144, 1996 190. Rosler A, Witztum E: Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med 338:416-422, 1998 191. Dallob AL, Sadick NS, Unger W, et al: The effect of finasteride, a 5 alpha-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 79:703-706, 1994

File: molecular-biology-of-the-androgen-receptor.pdf
Published: Thu Jun 13 12:47:08 2002
Pages: 15
File size: 1.22 Mb

Woman hating, 5 pages, 0.18 Mb

THE ASSOCIATION, 1 pages, 1.45 Mb
Copyright © 2018